KalVista (KALV) CFO sells 1,862 shares to cover RSU tax obligations
Rhea-AI Filing Summary
KalVista Pharmaceuticals Chief Financial Officer Brian Piekos reported routine equity compensation activity. On April 16, 2026, 6,250 restricted stock units (RSUs) converted into the same number of common shares for no cash consideration, reflecting scheduled vesting. On April 17, 2026, he sold 1,862 common shares at $20.2163 per share in an open-market transaction specifically to cover tax withholding obligations from the RSU vesting, described as a nondiscretionary “sell to cover” sale. After these transactions, he directly held 18,150 common shares, and 93,750 RSUs remained outstanding, which continue to vest quarterly in 1/16 increments starting April 16, 2026, subject to continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 1,862 | $20.2163 | $38K |
| Exercise | Restricted Stock Unit | 6,250 | $0.00 | $0.00 |
| Exercise | Common Stock | 6,250 | $0.00 | $0.00 |
Footnotes (3)
- F1. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
- F2. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
- F3. 1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on April 16, 2026, subject to continued service through each vesting date.
Key Figures
Key Terms
Restricted Stock Unit financial
sell to cover financial
tax withholding obligations financial
vesting Commencement Date financial
AI-generated analysis. How Rhea-AI works. Not financial advice.